Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.

McArthur MA, Kalu SU, Foulks AR, Aly AM, Jain SK, Patel JA.

Pediatr Infect Dis J. 2009 Dec;28(12):1127-9. doi: 10.1097/INF.0b013e3181acd17e.

PMID:
19820426
2.

[Complete auriculoventricular block in a patient treatment with Lopinavir/Ritonavir].

Jiménez FJ, Pinilla J, Repiso M, Labarga P.

Enferm Infecc Microbiol Clin. 2002 Oct;20(8):418. Review. Spanish. No abstract available.

PMID:
12372245
3.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland; Swiss Mother and Child HIV Cohort Study (MoCHiV).

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
4.

Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.

Resino S, Bellón JM, Muñoz-Fernández MA; Spanish Group of HIV Infection.

J Antimicrob Chemother. 2006 Mar;57(3):579-82. Epub 2006 Jan 30. No abstract available.

PMID:
16446377
6.

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.

J Antimicrob Chemother. 2008 Jan;61(1):183-90. Epub 2007 Nov 19.

PMID:
18025025
7.

Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.

Bates DE, Herman RJ.

Ann Pharmacother. 2006 Jun;40(6):1190-5. Epub 2006 May 23.

PMID:
16720703
8.
9.

[Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].

Moltó J, Clotet B.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 16:24-6. Review. Spanish.

PMID:
19572441
10.

Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.

Bongiovanni M, Chiesa E, Monforte Ad, Bini T.

Dermatol Online J. 2003 Dec;9(5):28. No abstract available.

PMID:
14996401
11.

Lopinavir/ritonavir. (Kaletra).

[No authors listed]

Res Initiat Treat Action. 2000 Dec;6(4):16-8. No abstract available.

PMID:
11708169
12.

A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.

Antoniou T, Park-Wyllie L, Boyle E.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1666-7. No abstract available.

PMID:
15577427
13.

Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.

[No authors listed]

TreatmentUpdate. 2008 Mar;20(2):5-6. No abstract available.

PMID:
18661644
14.

Lopinavir/ritonavir: a protease inhibitor combination.

[No authors listed]

Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2. No abstract available.

PMID:
11151088
15.

The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.

McCance-Katz EF, Rainey PM, Friedland G, Jatlow P.

Clin Infect Dis. 2003 Aug 15;37(4):476-82. Epub 2003 Aug 1.

PMID:
12905130
16.

Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2008 Jul;27(7):623-8. doi: 10.1097/INF.0b013e31816b4539.

PMID:
18520443
17.

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

Barragan P, Podzamczer D.

Expert Opin Pharmacother. 2008 Sep;9(13):2363-75. doi: 10.1517/14656566.9.13.2363 . Review.

PMID:
18710360
18.

Lopinavir.

Hurst M, Faulds D.

Drugs. 2000 Dec;60(6):1371-9; discussion 1380-1.

PMID:
11152017
19.

Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.

[No authors listed]

Prescrire Int. 2007 Aug;16(90):148.

PMID:
17724839
20.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083

Supplemental Content

Support Center